Medical use professional Typhoid Test kit, one step rapid test cassette

Clinical Sensitivity, Specificity and Accuracy

The Influenza A+B Antigen Rapid Test has been tested compared with RT-PCR. 539 nasopharyngeal swabs and oropharyngeal swabs were evaluated with the Influenza A+B Rapid Test.

Substances Concentration Substances Concentration
Nasal Spray 15% v/v Hemoglobin 10% v/v
Mucin 0.5 % w/v Mupirocin 10 mg/mL
Nasal Drops 15% v/v Mouthwash /
Chloraseptic 1.5 mg/mL Levofloxacin 40 ug/mL
 Oseltamivir 2ug/mL Ribavirin 0.2ug/mL
Fluticasone propionate 5% v/v Ceftriaxone 800 ug/mL
Tobramycin 4ug/mL Saline Nasal Spray 10% v/v

For Influenza A

Method RT-PCR Total Results
Influenza A+B Rapid Test Results Positive Negative
Positive 116 1 117
Negative 5 417 422
Total Results 121 418 539

Clinical sensitivity:95.87% (95% CI: 90.69%~98.22%) Clinical specificity:99.76% (95% CI: 98.66%~99.96%) Total Coincidence rate:98.89% (95% CI: 97.59%~99.49%).

For Influenza B:

Method RT-PCR Total Results
Influenza A+B Rapid Test Results Positive Negative
Positive 97 1 98
Negative 6 435 441
Total Results 103 436 539

Clinical sensitivity:94.17% (95% CI: 87.87%~97.30%) Clinical specificity:99.77% (95% CI: 98.71%~99.96%) Total Coincidence rate:98.70% (95% CI: 97.34%~99.37%).

Analytical Sensitivity/LOD

 img-1 Hangzhou Aichek Medical Technology CO., Ltd. Jinxing Cun, Yuhang Community, YuhangDistrict (Future Sci-Tech City), Hangzhou,Zhejiang, P.R. China
 img-2 SUNGO Europe B.V. Olympisch Stadion 24, 1076DE Amsterdam, Netherlands

The limit of detection (LOD) was identified by evaluating different concentrations of influenza A virus and influenza B virus in the Influenza A+B Antigen Rapid Test. The concentrations identified as the LOD levels tested are listed below. Influenza A (H3N2): 5×103 TCID50/mL Influenza A (H1N1): 2.5×103 TCID50/mL Influenza A (H1N1 pdm09): 2.5×103 TCID50/mL Influenza B (Yamagata): 3.5×103 TCID50/mL Influenza B (Victoria): 1.0×103 TCID50/mL

Analytical Specificity (Cross Reactivity)

To determine the analytical specificity of the Influenza A+B Antigen Rapid Test, several commensal or pathogenic microorganisms that may be present in the upper respiratory tract were tested. Positive and negative specimens were spiked with these microbes were evaluated at a concentration of 106 TCID50/mL, including SARS-CoV-2, Human coronavirus HKU1, OC43, NL63, 229E, MERS, Rhinovirus, Adenovirus, Enterovirus, Metapneumovirus, Parainfluenza, Respiratory syncytial virus, Mycoplasma pneumonia, Chlamydia pneumonia, Streptococcus pneumonia, Staphylococcus aureus, Mycobacterium tuberculosis, Haemophilus influenzae, Streptococcus pyogenes. No cross-reactivity was seen with the Influenza A+B Antigen Rapid Test.


Influenza A+B Antigen Rapid Test is a lateral flow immunoassay intended for the qualitative detection influenza A and influenza B antigens in nasopharyngeal swab and oropharyngeal swab.

Company Advantage

1. Professional Manufacturer, a national-level technologically advanced “giant” enterprise 2. Deliver goods as order request 3. ISO13485, CE, Prepare various shipping documents 4. Reply customers questions within 24 hours

Media Contact
Company Name: Hangzhou Hengsheng Medical Technology Co., Ltd.
Email: Send Email
Phone: +86-571-57127506
Country: China